If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Holding(s) in Company

16 Sep 2010 09:28

RNS Number : 7994S
GW Pharmaceuticals PLC
16 September 2010
 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

GW Pharmaceuticals

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Prudential plc group of companies

4. Full name of shareholder(s)  (if different from 3.):iv

See attached schedule

5. Date of the transaction and date on which the threshold is crossed or reached: v

14 September 2010

6. Date on which issuer notified:

15 September 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

See Item 13

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0030544687

16,124,500

16,124,500

16,429,500

16,429,500

0

12.65%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

16,429,500

12.65%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Prudential plc (parent Company)

M&G Group Limited (wholly owned subsidiary of Prudential plc)

M&G Limited (wholly owned subsidiary of M&G Group Limited)

M&G Investment Management Limited (wholly owned subsidiary of M&G Limited)

M&G Securities Limited (wholly owned subsidiary of M&G Limited)

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

 

M&G Securities Limited (wholly owned subsidiary of M&G Limited) has moved to a 11% notifiable interest triggering this notification.

 

14. Contact name:

Ryan Dowling / Mark Thomas

M&G Investment Management Limited

15. Contact telephone number:

020 7548 2979 / 020 7548 3266

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAPNKFAKEEEF
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.